Change search
ReferencesLink to record
Permanent link

Direct link
Human Serum Metabolites Associate With Severity and Patient Outcomes in Traumatic Brain Injury
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland; Steno Diabetes Center A/S, Gentofte, Denmark; VTT Technical Research Centre of Finland, VTT, Espoo, Finland.
Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, Finland; Division of Clinical Neurosciences, Department of Rehabilitation and Brain Trauma, Turku University Hospital, Turku, Finland; Department of Neurology, University of Turku, Turku, Finland.
Steno Diabetes Center A/S, Gentofte, Denmark.
Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, Finland.
Show others and affiliations
2016 (English)In: EBioMedicine, ISSN 0360-0637, E-ISSN 2352-3964, Vol. 12, 118-126 p.Article in journal (Refereed) Published
Abstract [en]

Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults. TBI is an example of a medical condition where there are still major lacks in diagnostics and outcome prediction. Here we apply comprehensive metabolic profiling of serum samples from TBI patients and controls in two independent cohorts. The discovery study included 144 TBI patients, with the samples taken at the time of hospitalization. The patients were diagnosed as severe (sTBI; n=22), moderate (moTBI; n=14) or mild TBI (mTBI; n=108) according to Glasgow Coma Scale. The control group (n=28) comprised of acute orthopedic non-brain injuries. The validation study included sTBI (n=23), moTBI (n=7), mTBI (n=37) patients and controls (n=27). We show that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also detected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from TBI patients at the time of hospitalization, an algorithm was developed that accurately predicted the patient outcomes (AUC=0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH), comprising clinical and computed tomography data, significantly improved prediction of patient outcomes. The identified 'TBI metabotype' in serum, that may be indicative of disrupted blood-brain barrier, of protective physiological response and altered metabolism due to head trauma, offers a new venue for the development of diagnostic and prognostic markers of broad spectrum of TBIs. (C) 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Place, publisher, year, edition, pages
Elsevier, 2016. Vol. 12, 118-126 p.
Keyword [en]
Biomarkers, Mass spectrometry, Metabolomics, Traumatic brain injury
National Category
Family Medicine
URN: urn:nbn:se:oru:diva-53704DOI: 10.1016/j.ebiom.2016.07.015ISI: 000386878500026PubMedID: 27665050ScopusID: 2-s2.0-84992650319OAI: oai:DiVA.org:oru-53704DiVA: diva2:1051129
Available from: 2016-12-01 Created: 2016-12-01 Last updated: 2016-12-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Hyötyläinen, Tuulia
By organisation
School of Science and Technology, Örebro University, Sweden
In the same journal
Family Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link